Daiichi Sankyo enrolls first patient in Nimotuzumab Phase 3 clinical trials
25 April 2013 | By Daiichi Sankyo
The first patient has been enrolled in two pivotal phase 3 clinical trials of nimotuzumab...
List view / Grid view
News
Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study
25 April 2013 | By Sanofi
Genzyme announced positive top-line results from the TOPIC trial for AUBAGIO...
Sanofi and DNDi celebrate six years of collaboration in fighting malaria
25 April 2013 | By Sanofi
More than 200 million treatments of ASAQ Winthrop have been distributed in Africa...
Novartis signs on to support Malaria No More’s Power of One campaign to stride towards a future without malaria
25 April 2013 | By Novartis
"We believe that this innovative campaign will help speed malaria elimination..."
Pfizer receives CHMP negative opinion regarding marketing authorization in Europe for Rheumatoid Arthritis treatment XELJANZ® (tofacitinib citrate)
25 April 2013 | By Pfizer
Pfizer intends to appeal and seek re-examination...
AAPS 2013: Gerresheimer presents its glass and plastic pharmaceutical packaging products
25 April 2013 | By Gerresheimer
Requirements of innovative packaging products are getting increasingly stringent...
Janssen submits Marketing Authorisation Application for Simeprevir to the EMA
24 April 2013 | By Burson-Marsteller
Janssen has submitted a MAA to the EMA seeking approval for simeprevir...
Sanofi Pasteur to provide 1.7 billion doses of oral polio vaccine from 2013 to 2017 for polio eradication
24 April 2013 | By Sanofi Pasteur
Company also expands injectable polio vaccine production capacity...
Novartis discloses compensation for new Chairman and Chairman ad-interim
24 April 2013 | By Novartis
Novartis announced the compensation for the incoming Chairman of the Board, starting August 1, 2013...
Boehringer Ingelheim consistently continues growth phase in financial year 2012
24 April 2013 | By Boehringer Ingelheim
Net sales rose by 11.5 percent to around €14.7 billion...
Merck to present updated interim data from Phase II trial
23 April 2013 | By Merck
Merck announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial...
Teva and Xenon announce FDA orphan drug designation for pain drug XEN402
23 April 2013 | By TEVA
"We are very pleased to receive orphan drug designation for XEN402..."
Data from Phase 3 studies of Gilead’s sofosbuvir for hepatitis C to be presented at 48th Annual EASL Meeting
23 April 2013 | By Gilead Sciences
Detailed results from four Phase 3 clinical trials...
Alchemia announces multi-target drug discovery collaboration with AstraZeneca on VAST discovery platform
23 April 2013 | By Alchemia Limited
Alchemia has signed a multi-target, drug discovery collaboration with AstraZeneca...
Boehringer Ingelheim announces results from one of its HCV Phase III trials
23 April 2013 | By Boehringer Ingelheim
Results from the pivotal Phase III STARTVerso™1 trial...
